Brand semaglutide
Sold by Maven Clinic · Injection, pen · every brand semaglutide record
What you actually pay
Per month
$349
| Medication · Wegovy Pen, self-pay | $199 |
|---|---|
| Required membership | $150 |
Added from the figures recorded below.
Price
| Term | Per month | Charged today |
|---|---|---|
| Wegovy Pen, self-pay “Wegovy® Pen Prefilled GLP-1 injection that regulates appetite and supports weight loss and fatty liver improvement $199 /mo self-pay | Starting from $25 /mo with insurance” source, read September 2, 2026 | Per month$199 | Charged today$199 |
| Wegovy Pen, with insurance (starting from) “$199 /mo self-pay | Starting from $25 /mo with insurance” source, read September 2, 2026 | Per month$25 | Charged today$25 |
We earn nothing from this link. Maven Clinic has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
History
- September 2, 2026 — $199
- September 3, 2026 — $199
- September 2, 2026 — Entry added to the register
Sourcing and terms
| Prescriber | Both |
|---|---|
| Membership | Required. $150 per month. “$150 / month after Medication costs separate—as low as $149/mo for self-pay” |
| Consult fee | None. “Two free specialist consultations (nutrition & strength training)” |
Not yet checked: pharmacy, states and cancellation.
Recorded from mavenclinic.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. September 2, 2026 — Company confirmed via own site (title 'Maven Clinic - The next generation of care for women and families', footer '© 2026 Maven Clinic Co.'). This is exactly the membership-vs-medication trap the brief warns about: the 'glp-1 care membership' is $150/month (first month discounted to $39 per the pricing section: 'glp-1 care membership $150 $39 / first month Then $150 /month') and covers clinician visits, two specialist consultations, dose adjustments, and side-effect management -- it explicitly does NOT include the medication ('Medication costs separate'). Medication is billed separately by the pharmacy at self-pay or insurance rates listed per product; both self-pay and insurance ('starting from') figures are recorded as separate price entries per drug/form, labeled accordingly, per the insurance-vs-cash-price rule. 'Foundayo' is described only as 'Oral GLP-1 pill' with no active ingredient named on any page checked, so it was classified as unspecified GLP-1 rather than assumed to be semaglutide. The Zepbound Pen self-pay price is printed as an open-ended '$1,000+/mo' (not a fixed number); recorded perMonth as the floor value with the exact quote showing it is open-ended. No explicit state-availability list or cancellation policy was found on the marketing pages checked (the GLP-1 safety-information legal page is JavaScript-rendered and returned no text).
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.